WALTHAM, Mass., June 28 /PRNewswire/ -- Millennium Research Group (MRG), the global authority on medical technology market intelligence, has learned that Medtronic is launching KYPHON ActivOs 10 Bone Cement, a new type of bone cement in the U.S. for patients who suffer from vertebral fractures.
There are two types of vertebral compression fracture treatments: vertebroplasty and vertebral augmentation, the latter of which includes kyphoplasty. Both procedures require the placement of bone cement into the fractured vertebra through a small incision under X-ray guidance. The vast majority of cement used in vertebroplasty and vertebral augmentation procedures is polymethylmethacrylate. Polymethylmethacrylate is a medical grade substance that has been used for many decades in a variety of orthopedic procedures. Bone cement manufacturers have developed numerous bone cement protocols to adhere to diverse procedural requirements by altering such properties as viscosity, biocompatibility, mechanical stability, chemical stability, and antibiotic release. Because the KYPHON ActivOs 10 Bone Cement contains hydroxyapatite, which is chemically and structurally similar to the mineral component of bone, according to a statement from Medtronic, the product should be more bioactive than traditional polymethylmethacrylate cement.
MRG's Orthopedics Division Manager, Kevin Flewwelling, is available to offer extensive expertise on this announcement. Mr. Flewwelling can comment on:
- How KYPHON ActivOs 10 Bone Cement compares to other available vertebral compression fracture treatment bone cements
- The impact of new product releases and emerging competitors in the vertebral compression fracture treatment market
- How the release of the KYPHON ActivOs 10 Bone Cement positions Medtronic in response to mounting competition from CareFusion and Stryker Interventional Spine
"The global minimally invasive vertebral compression fracture treatment market will grow robustly over the next five years," says Mr. Flewwelling. "However, the market certainly has seen its fair share of twists and turns since two articles were published in the New England Journal of Medicine last August that questioned the efficacy of vertebroplasty. On top of that, competitive pressures in this market have heated up following CareFusion's and Stryker Interventional Spine's release of their own vertebral augmentation systems in March and April. These recent events represent the strongest challenge to Medtronic's dominance of the vertebral augmentation market thus far."
MRG's global orthopedics expertise covers vertebral compression fracture treatments, spinal fusion and nonfusion technologies, orthopedic biomaterials, reconstructive joints, trauma fixation, soft tissue treatments, and more.
To arrange an interview with Mr. Flewwelling, please contact Amy Krohn at 416-364-7776 ext. 101 or firstname.lastname@example.org.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Millennium Research Group